Eliava Phage Therapy Center
Eliava Phage Therapy Center is a private Tbilisi-based outpatient clinic specializing in bacteriophage therapy for international patients with antibiotic-resistant infections, offering local and telemedicine treatment courses plus custom phage preparations.
- Company typePrivate
- Founded2001
- HeadquartersTbilisi, Georgia
- Headcount11–50
- GTM typeB2C
- OfferingServices
What Eliava Phage Therapy Center does
Eliava Phage Therapy Center (EPTC) is a private outpatient medical clinic headquartered at 3 Gotua Street, Tbilisi, Georgia, established in 2001 as the clinical arm of the Eliava Institute of Bacteriophages, Microbiology and Virology — a research institute founded in 1923 by Prof. George Eliava in collaboration with Felix d'Herelle. EPTC specializes in bacteriophage (phage) therapy, using naturally occurring viruses that selectively infect and destroy bacteria as an alternative to antibiotics for patients with antibiotic-resistant infections (including MRSA, VRE, CRE, and ESBL), chronic recurrent infections, or antibiotic intolerance. The clinic operates across eight clinical specialties — Internal Medicine, Urology & Gynecology, Pediatrics, ENT, Surgery, Dermatology, Massage & Physiotherapy, and Laboratory & Diagnostics — and is supported by the vertically integrated Eliava Consortium, which includes the Eliava Institute's century-old phage collection, the Eliava Diagnostic Center (bacteriological analysis and phage sensitivity testing), the Eliava Authorized Pharmacy (compounding under a special Georgian Ministry license), Eliava BioPreparations (manufacturing six standard products plus custom preparations), and the Georgian-American Diagnostic Center (imaging).
The commercial offering is organized around three products: a Local Treatment Course priced at €4,200 covering 10 workdays of in-clinic diagnostics, multidisciplinary consultations, supportive therapies, and take-home phage preparations; a Distance Treatment Course priced at €2,100 covering telemedicine consultations via Doxy.me and international shipment of phage preparations to patients unable to travel; and Custom (Autophage) Preparations at €1,500 per 20 boxes for resistant strains, with 8–12 week lead time and €900 repeat pricing. Telemedicine maintains HIPAA, GDPR, PHIPA/PIPEDA, and HITECH compliance. The go-to-market is direct-to-consumer: patients self-refer, submit bacterial samples for sensitivity testing, and complete intake via the website or social channels (Facebook, Instagram, YouTube, LinkedIn). Distribution reaches globally, with phage preparations shipped to multiple countries via international courier (subject to local import licensing), and marketing amplified by international earned media (BBC, CNN, Stat News, The Atlantic, The Telegraph).
Revenue mechanics are professional-services-based: episodic per-course fees rather than subscriptions, denominated in Euros with cash or bank-transfer settlement. The clinic has 14 employees, is led by Chief Physician Dr. Dea Nizharadze, and has no disclosed funding rounds, external investors, or public financial filings. Parent affiliation with the Eliava Institute and operation within the Eliava Consortium provide a structural moat through the historic phage library and clinical expertise accumulated since 1923, but the business remains a small, privately held specialty medical practice with thin publicly observable financial data.
Eliava Phage Therapy Center firmographics
Firmographics- Name
- Eliava Phage Therapy Center
- Legal name
- Eliava Phage Therapy Center
- Website
- https://eptc.ge
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Eliava Phage Therapy Center is a private Tbilisi-based outpatient clinic specializing in bacteriophage therapy for international patients with antibiotic-resistant infections, offering local and telemedicine treatment courses plus custom phage preparations.
- Ownership category
- akta.pro rank
Where Eliava Phage Therapy Center is headquartered
LocationHeadquarters
- HQ city
- Tbilisi
- HQ country
- Georgia
- HQ region
- Asia
Offices2 records
Markets served
Eliava Phage Therapy Center business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Local Treatment Services: Comprehensive in-person treatment course at the Tbilisi clinic including diagnostics, consultations, phage therapy, and supportive services. Priced at 4200 Euro per course.
- Distance Treatment Services: Telemedicine consultations and phage preparation shipping for patients unable to travel. Priced at 2100 Euro per course.
- Custom Phage Preparations: Individualized phage preparations for resistant bacteria, priced at 1500 Euro for initial 20 boxes (8-12 week preparation time), 900 Euro for repeat orders
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Local Treatment Course - 4200 Euro |
| One time/ perpetual license | Multi-year contract | Distance Treatment Course - 2100 Euro |
| Unit Pricing | Pay-as-you-go | Custom Phage Preparations - 1500 Euro (initial) / 900 Euro (repeat) |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Eliava Phage Therapy Center product offering
Product offeringCore offering
Eliava Phage Therapy Center provides bacteriophage (phage) therapy as a medical treatment for antibiotic-resistant and chronic bacterial infections. It offers two core treatment programs: an in-person Local Treatment Course at its Tbilisi, Georgia clinic and a Distance Treatment Course delivered via telemedicine with phage preparations shipped internationally. Services span multiple medical specialties and include custom phage preparations, laboratory diagnostics, and supportive physiotherapy.
Product overview
Eliava Phage Therapy Center offers phage therapy as a unified medical service centered on bacteriophage treatment for antibiotic-resistant bacterial infections. The core offerings are two treatment programs: the Local Treatment Course (4,200 Euro, in-person at Tbilisi clinic) and Distance Treatment Course (2,100 Euro, remote). Custom phage preparations are available as an add-on for individualized treatment. The center operates across multiple medical specialties (Internal Medicine, Pediatrics, Urology/Gynecology, ENT, Surgery, Dermatology) and provides integrated support services including laboratory diagnostics, physiotherapy, and massage therapy. All treatments emphasize bacteriophage preparations as the cornerstone of complex medical services.
Differentiator
Problem solved
Functional benefit
Products and services
- Local Treatment Course In-person phage therapy treatment at the EPTC clinic in Tbilisi, Georgia, lasting 10 workdays. Includes registration, primary care consultation, lab work, diagnostic investigations, commencement of phage therapy, multidisciplinary team consultations, supportive services (therapeutic massage, physiotherapy), continuous phage therapy with adjustments, repeat bacteriological analysis, and phages provided for home use. Priced at 4,200 Euro.
- Distance Treatment Course
- Custom Phage Preparations (Autophage)
- Internal Medicine Phage Therapy
- Urology & Gynecology Phage Therapy
- Pediatric Phage Therapy
- ENT Phage Therapy
- Surgical Infections Phage Therapy
- Dermatology Phage Therapy
- Laboratory & Diagnostic Services
- Massage & Physiotherapy
Companies that use Eliava Phage Therapy Center
Customer profileNamed customers1 record
Segments6 records
Ideal customer profiles1 record
Eliava Phage Therapy Center technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature3 records
Eliava Phage Therapy Center partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, major and minor.
- Eliava Institute of Bacteriophages, Microbiology and VirologycoreParent research institution founded in 1923 by Prof. George Eliava. Provides the foundational phage research, collection, and expertise that EPTC leverages for clinical applications.
- Eliava FoundationcoreNon-profit organization established by scientists from the Eliava Institute. Part of the Eliava Consortium joint venture.
- Eliava BioPreparationscoreSpin-off company developing and manufacturing therapeutic and prophylactic bacteriophage preparations. Produces six standard bacteriophage products and custom preparations.
- Eliava Diagnostic Center (Diagnozi 90)coreEstablished in 1990 by leading Eliava scientists. Provides extensive microbiological and clinical laboratory services including bacteriological analysis and phage sensitivity testing. 36 employees including 12 with state laboratory medicine certificates.
- Georgian-American Diagnostic CentermajorDiagnostic partner providing MRI, CT, ultrasound, densitometry, and X-ray services with protocols according to American Radiology Association. Images reviewed by American radiologists.
- Eliava Authorized PharmacycorePharmacy established in 2013 producing customized bacteriophage preparations. Holds special license from Georgian Ministry for compounding and personalized medications.
- Tourism AgenciesminorPartner agencies providing accommodation (e.g., Ameri Plaza hotel) and airport transfer services for international patients visiting the clinic.
Scale indicators3 records
Recent moves8 records
Expansion highlights6 records
Eliava Phage Therapy Center competitors and assessment
Company assessmentOthers
- The Eliava Institute of Bacteriophages, Microbiology and Virology: Parent research institution founded in 1923 that supplies EPTC's phage collection and scientific expertise. Not a direct market competitor but the closest enabling partner; understanding the institute is essential context for evaluating EPTC's moat.
Emerging players
- Eligo Bioscience: France-based biotech developing engineered phage-based precision medicines to target specific bacterial pathogens. Comparable scientific approach to selective bacterial elimination.
- ContraFect: US biotech developing direct lytic agents and phage-derived lysins for serious bacterial infections including MRSA. Comparable in addressing antibiotic-resistant infections though using phage-derived rather than whole phage approaches.
- BiomX: Israel-based clinical-stage company developing phage-based therapies for conditions including cystic fibrosis and IBD. Comparable in therapeutic area and patient target populations.
- Locus Biosciences: US-based clinical-stage company developing engineered phage therapies targeting resistant bacterial infections in the urinary tract and other indications. Comparable therapeutic focus with regulatory pathway approach.
- PhagePro: US-based startup focused on prophylactic and therapeutic phage applications for infectious disease, with research ties to Tufts University. Comparable in clinical phage therapy development pipeline.
Direct peers
- Phagelux: China-based phage therapy company developing both human therapeutic phage products and animal health applications. Direct peer operating in the global phage therapy market.
- Intralytix: US-based phage technology company with FDA-approved phage products for food safety and a clinical pipeline targeting human bacterial infections. Direct peer in therapeutic bacteriophage development.
- Adaptive Phage Therapeutics: US-based clinical-stage phage therapy company developing personalized phage treatments for antibiotic-resistant infections. Closest direct competitor in the personalized phage therapy space, though focused on US regulatory pathways rather than international patient travel.
- TechnoPhage: Portugal-based biotech company developing bacteriophage products for bacterial infections, with focus on respiratory and skin infections. Direct peer in clinical phage therapy development.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Eliava Phage Therapy Center social profiles
Digital presenceEliava Phage Therapy Center compliance and trust
Trust signalCompliance4 records
Eliava Phage Therapy Center financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eliava Phage Therapy Center leadership team
Management profileNumber of profiles
Profiles7 records
Eliava Phage Therapy Center funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eliava Phage Therapy Center M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eliava Phage Therapy Center
What does Eliava Phage Therapy Center do?
Eliava Phage Therapy Center provides bacteriophage (phage) therapy as a medical treatment for antibiotic-resistant and chronic bacterial infections. It offers two core treatment programs: an in-person Local Treatment Course at its Tbilisi, Georgia clinic and a Distance Treatment Course delivered via telemedicine with phage preparations shipped internationally. Services span multiple medical specialties and include custom phage preparations, laboratory diagnostics, and supportive physiotherapy.
Is Eliava Phage Therapy Center a public or private company?
Eliava Phage Therapy Center is a private company. It is classified as corporate owned and is currently operating.
When was Eliava Phage Therapy Center founded?
Eliava Phage Therapy Center was founded in 2001. It employs 11 to 50 people.
Where is Eliava Phage Therapy Center based?
Eliava Phage Therapy Center is headquartered in Tbilisi, Georgia, in the Asia region.
How does Eliava Phage Therapy Center make money?
Three revenue lines are on record. Local Treatment Services are the primary driver. The others are distance Treatment Services and custom Phage Preparations.
Who are Eliava Phage Therapy Center's main competitors?
The Eliava Institute of Bacteriophages, Microbiology and Virology is listed as an others. Emerging players are Eligo Bioscience, ContraFect, BiomX, Locus Biosciences and PhagePro. Direct peers are Phagelux, Intralytix, Adaptive Phage Therapeutics and TechnoPhage.
Does Eliava Phage Therapy Center have an API?
No public API is recorded for Eliava Phage Therapy Center.